-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

Benzinga·07/31/2026 14:12:02
語音播報
Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.